Degarelix

What is Degarelix?

Degarelix is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that produces rapid medical castration by competitively blocking pituitary GnRH receptors. Unlike the older and more widely used GnRH agonists (leuprolide, triptorelin, goserelin, buserelin, nafarelin, histrelin) — which paradoxically suppress the reproductive axis after an initial 1–2 week stimulatory 'flare' — degarelix blocks GnRH receptors directly from the first dose, collapsing LH, FSH, and testosterone without any transient rise. This flare-avoidance is its defining clinical advantage. Developed by Ferring Pharmaceuticals and FDA-approved in December 2008 as Firmagon for advanced prostate cancer, it was the first commercially successful injectable GnRH antagonist and remained the only FDA-approved injectable antagonist in the class until the oral agent relugolix (Orgovyx) arrived in 2020.

What Degarelix Is Investigated For

Degarelix is FDA-approved for advanced prostate cancer and sits in the same therapeutic space as the GnRH agonists (leuprolide, triptorelin, goserelin) but with a mechanistically different approach: direct competitive antagonism of the pituitary GnRH receptor, producing castrate testosterone (<50 ng/dL) in the majority of men within 3 days of the first dose and no testosterone flare at all. The strongest evidence is the pivotal CS21 phase 3 trial (Klotz 2008, n=610) showing non-inferior 12-month testosterone suppression versus leuprolide with dramatically faster onset, and the 5-year CS21A extension (Crawford 2014) demonstrating durable control. Pooled analysis across five trials (Klotz/Tombal 2014) suggested improved PSA progression-free survival and overall survival with degarelix versus LHRH agonists, and exploratory data show better control of serum alkaline phosphatase in men with bone metastases. The clearest clinical niche is the patient who cannot tolerate a testosterone flare — impending spinal cord compression, symptomatic high-burden bone metastases, or ureteral obstruction — where standard-of-care with an agonist would require 2–4 weeks of anti-androgen cover that degarelix sidesteps entirely. A second niche is suggested but not proven: patients with significant pre-existing cardiovascular disease, where registry data and some meta-analyses suggest a lower cardiovascular event rate, though the prospective PRONOUNCE trial was terminated early and underpowered and did not conclusively confirm this advantage. The real-world trade-offs are injection-site reactions (roughly 40% of patients, mostly with the loading dose) and monthly rather than 3- or 6-monthly dosing.

History & Discovery

Degarelix emerged from the decades-long effort to build clinically useful GnRH antagonists as an alternative to the GnRH agonist class that had defined prostate cancer androgen deprivation since leuprolide's 1985 approval. The conceptual appeal of antagonists was obvious from the moment leuprolide entered practice: direct blockade of the pituitary GnRH receptor would suppress testosterone immediately, without the paradoxical 1–2 week 'flare' that agonists produce and without the clinical need for anti-androgen cover during that window. The problem was pharmacological — the first- and second-generation GnRH antagonists had unacceptable histamine-release profiles. Abarelix (Plenaxis, Praecis Pharmaceuticals), the first commercial injectable GnRH antagonist, received FDA approval in 2003 but was withdrawn from the US market in 2005 because of serious systemic allergic reactions that limited its viability. The earlier antagonists cetrorelix and ganirelix found roles in fertility medicine (IVF cycle control) but not in the chronic-dosing prostate cancer setting. Degarelix (FE200486) was developed by Ferring Pharmaceuticals — the company that, notably, had also developed desmopressin and several other peptide drugs — with research sited in San Diego. The molecule is a decapeptide with multiple D-amino acid substitutions and non-natural residues that achieve high GnRH receptor affinity, metabolic stability, and — critically — minimal histamine release. Ex vivo human skin histamine-release studies (Broqua 2010) directly demonstrated that degarelix has dramatically lower histamine-releasing potential than abarelix, cetrorelix, and ganirelix, and the clinical program confirmed that the systemic allergic reactions that had plagued abarelix did not occur with degarelix. The pivotal CS21 phase 3 trial (Klotz 2008, n=610) compared two degarelix regimens (240/80 mg and 240/160 mg) against monthly leuprolide 7.5 mg for 12 months in advanced prostate cancer. Non-inferiority for 12-month testosterone suppression was demonstrated, and degarelix's defining advantage — castrate testosterone in ~96% of men by day 3 versus none with leuprolide — was clearly established. FDA approved Firmagon (degarelix) on December 24, 2008 for advanced prostate cancer, making it Ferring's first US drug approval and the first commercially successful injectable GnRH antagonist. The long-term follow-on evidence — the CS21A 5-year extension (Crawford 2014), the pooled five-trial analysis (Klotz and Tombal 2014), the German IQUO real-world registry, and a growing body of observational cardiovascular comparisons — has positioned degarelix as a niche but meaningful therapy: the agent of choice when testosterone flare must be avoided, and a class alternative for men with significant cardiovascular disease who may benefit from avoiding the agonist class. The prospective PRONOUNCE cardiovascular trial, designed to confirm the cardiovascular advantage, was terminated early and was ultimately inconclusive. The 2020 arrival of oral relugolix (Orgovyx), a small-molecule GnRH antagonist with once-daily oral dosing, has reshaped the broader antagonist space — relugolix's HERO trial did show a cardiovascular advantage over leuprolide — but degarelix remains the injectable option in the class and the agent with the longest track record for rapid-suppression niche indications.

How It Works

Degarelix blocks the brain's GnRH receptor directly, like flipping a switch off. This immediately stops LH and FSH release from the pituitary, which collapses testosterone production within days. Unlike the older GnRH agonists (leuprolide, triptorelin), which have to first over-stimulate the receptor for 1–2 weeks before shutting it down, degarelix has no initial testosterone surge — useful when a surge would be clinically dangerous, like in men with spinal bone metastases.

Degarelix is a synthetic decapeptide GnRH receptor antagonist (Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-Hor)-D-4Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2) that competitively and reversibly binds the pituitary GnRH receptor with high affinity, blocking endogenous GnRH from triggering Gq/11-coupled signaling and gonadotropin release. Unlike GnRH agonists — which cause receptor desensitization via sustained overstimulation and thus produce the characteristic 1–2 week flare — degarelix's direct antagonism collapses LH and FSH within hours of the loading dose, with castrate testosterone (<50 ng/dL) achieved in ~96% of men by day 3. FSH suppression is notably deeper and more sustained than with GnRH agonists (88.5% reduction with degarelix 240/80 mg versus 54.8% with leuprolide at 12 months in CS21), which may contribute to differential effects on skeletal and prostate outcomes. Degarelix forms a slow-release subcutaneous depot at the injection site; the terminal half-life is approximately 53 days, reflecting slow release from this depot rather than intrinsic molecular half-life. Clearance is mixed hepato-biliary and renal (approximately 70–80% hepato-biliary, 20–30% renal). Notably, degarelix has minimal histamine-releasing potential in ex vivo human skin models compared with earlier GnRH antagonists (abarelix, cetrorelix, ganirelix), which explains the absence of the systemic allergic reactions that derailed abarelix's clinical use.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Degarelix:

• 01Cardiovascular outcomes versus GnRH agonists — the prospective PRONOUNCE trial was terminated early and underpowered, leaving the cardiovascular advantage suggested by registry and meta-analysis data formally unproven in a head-to-head RCT of injectable antagonist versus agonist. The oral antagonist relugolix's HERO trial did show a cardiovascular advantage, supporting but not proving the class-level hypothesis for degarelix specifically.
• 02Comparison with oral relugolix — head-to-head comparative effectiveness and safety data between injectable degarelix and oral relugolix within the antagonist class are limited; selection is currently driven by patient preference (injection vs. pill), insurance coverage, and clinician familiarity.
• 03Optimal role in neoadjuvant protocols before radical prostatectomy or radiotherapy — the ARNEO trial explored degarelix plus apalutamide in a neoadjuvant setting, but the broader question of whether antagonist-based neoadjuvant ADT outperforms agonist-based neoadjuvant ADT for pathologic or long-term outcomes is incompletely resolved.
• 04FSH suppression clinical implications — degarelix suppresses FSH more deeply than GnRH agonists, and some investigators hypothesize this contributes to differential effects on bone health, cardiovascular risk, and prostate cancer control. The clinical significance is plausible but not definitively demonstrated.
• 05Long-term (>5 year) safety data — the CS21A extension provided 5-year data, but decade-plus safety and efficacy data comparable to what exists for leuprolide are still accumulating.
• 06Intermittent ADT with antagonists — faster post-discontinuation testosterone recovery is a plausible advantage of degarelix for intermittent-ADT protocols, but dedicated trials testing this potential benefit are limited.
• 07Degarelix monotherapy in biochemical recurrence — the niche where an agent with faster onset and faster recovery might be particularly useful is incompletely characterized by head-to-head trials.

Forms & Administration

Subcutaneous injection only, administered in the abdomen. Loading dose: 240 mg given as two separate 120 mg subcutaneous injections at 40 mg/mL concentration. Maintenance dose: 80 mg subcutaneously every 28 days at 20 mg/mL concentration, beginning 28 days after the loading dose. Injection site should be varied and not placed in areas where the patient will be exposed to pressure (waistband, belt). All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Degarelix is FDA-approved only for advanced prostate cancer. It should be prescribed and monitored by a clinician familiar with androgen-deprivation therapy and its consequences. It is not a wellness peptide and has no legitimate non-oncologic role.

Timeline of Effects

Common Questions

Who Degarelix Is NOT For

Drug & Supplement Interactions

Degarelix has a relatively simple classical drug-interaction profile because peptide proteolytic clearance does not engage CYP-mediated metabolism. The clinically important interactions are largely pharmacodynamic. QT-prolonging medications: degarelix, like all androgen-deprivation therapies, can prolong QT interval, and combination with Class IA and III antiarrhythmics, certain antiemetics, fluoroquinolones, macrolides, methadone, and certain antipsychotics warrants ECG monitoring and electrolyte management. This is a class effect of androgen deprivation rather than something unique to degarelix. Anti-androgens (bicalutamide, flutamide, enzalutamide, apalutamide, darolutamide): co-administration with anti-androgens is not required with degarelix because there is no flare to cover — but combined androgen blockade or sequencing with second-generation anti-androgens for advanced disease is clinically common and well-tolerated. Diabetic medications: long-term ADT alters insulin sensitivity and increases diabetes risk; patients on insulin or oral antihyperglycemics may need dose adjustment over months of therapy. Glycemic monitoring is part of routine ADT follow-up regardless of agent. Antihypertensives and cardiac medications: ADT affects lipid profiles and cardiovascular physiology; medication adjustments may be needed over time. The cardiovascular question is whether degarelix carries a smaller risk signal than GnRH agonists — the signal is suggestive but not conclusive. Warfarin and other anticoagulants: minimal documented direct pharmacokinetic interaction, but overall metabolic and weight shifts during ADT can affect anticoagulation control; INR monitoring should continue as usual. Corticosteroids: commonly used together in prostate cancer for symptom management and for managing injection-site reactions; the combination is intended and well-tolerated. As with any chronic specialty therapy, patients should disclose all prescription, OTC, and supplement use to their prescriber.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions